As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: August 1, 2015
A new drug to treat Alzheimer’s disease may be four times more effective than the current medication in improving the brain power of patients, Australian researchers say.
Trial leader associate professor Steve Macfarlane, Caulfield Hospital director of Aged Psychiatry, said he was “cautiously optimistic” about the drug trial of Anavex 2-73 in patients with the early stage of the disease.
As part of the trial the researchers analysed the electrical activity in patient’s brains, which is a measure of cognition, ‘Herald Sun’ reported.
“This drug seems to improve electrical markers by four times more than the current standard of care drug, which is a medication called donepezil (Aricept),” Macfarlane said.
The result, which came after 36 days of therapy, is already higher than what donepezil reaches after six months of taking it continuously, researchers said.
“We’ve also had patients and their carers reporting improvements in their thinking, increased alertness and improvement in their organisation and independence,” Macfarlane said.
“It seems to be hitting the receptors that it is meant to and be having the desired result in improving brain activity,” Macfarlane said.
The final results of the study, which will involve 32 people in total, should be known by the end of the year, researchers said.
However, Macfarlane said while it was important to recognise the positive results of the trial, they were only preliminary.
The preliminary results of the study were presented at the 2015 Alzheimer’s Association International Conference (AAIC) in the US.
Join us for conversation and reception with 8-time Juno Award winning Singer-Songwriter & Actress Jann Arden, along with Your Morning Host Anne-Marie Mediwake. Whether she is captivating audiences with her heartfelt music, entertaining them with...
Chronic pain can impact everything from your mood, to your sleep to your social life. “The first things we lose are fun activities and leisure and we end up only doing what we...
A team of researchers, led by NYU Abu Dhabi Assistant Professor of Biology Mazin Magzoub, has developed small proteins called cell-penetrating peptides (CPPs) that prevent the aggregation of the amyloid-β (Aβ) protein associated with Alzheimer’s disease....
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.